who discovered glp-1 agonists Glucagon-like peptide-1 GLP-1 medications were first introduced

Fatigue is listed as a common adverse effect in FDA prescribing information for several GLP-1 receptor agonists

Third, although the notion of enhancing healthspan and potentially prolonging lifespan through GLP-1 RA treatment is appealing, its application to asymptomatic individuals in clinical settings is still primarily theoretical and lacks robust empirical support at this time

The concern stems from the fact that these drugs promote cellular proliferation in the intestines, potentially leading to tumorigenesis

Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities

A 2025 Stanford University interview with psychiatrist Anna Lembke touches on positive connections between the dopamine-stabilizing effects of GLP-1 medications on food addictions and the similar needs of patients with other drug addiction issues

After 4 weeks of 0.25 mg, increase dose to 0.5 mg once weekly